[
  {
    "title": "汇宇制药(688553.SH)：股东王晓鹏完成减持1.737%股份",
    "href": "http://stock.jrj.com.cn/2023/01/06181137264945.shtml",
    "datetime": "2023-01-06 18:11:25",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：重组Ⅲ型人源化胶原蛋白溶液的注册申请获得受理",
    "href": "http://stock.jrj.com.cn/2023/01/04162337258523.shtml",
    "datetime": "2023-01-04 16:23:54",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：上海爽飒已累计减持2.368%的股份",
    "href": "http://stock.jrj.com.cn/2022/12/22182537232093.shtml",
    "datetime": "2022-12-22 18:25:12",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：紫杉醇注射液获得德国上市许可",
    "href": "http://stock.jrj.com.cn/2022/12/22181837232060.shtml",
    "datetime": "2022-12-22 18:18:37",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：上海爽飒持股比例由13.030%减至11.977%",
    "href": "http://stock.jrj.com.cn/2022/12/20183037226235.shtml",
    "datetime": "2022-12-20 18:30:02",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：核心技术人员滕毓敏离职",
    "href": "http://stock.jrj.com.cn/2022/12/14162537212075.shtml",
    "datetime": "2022-12-14 16:25:32",
    "code": "688553"
  },
  {
    "title": "汇宇制药：黄乾益拟减持不超过2%",
    "href": "http://stock.jrj.com.cn/2022/12/05164537188901.shtml",
    "datetime": "2022-12-05 16:45:59",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：持股14.401%股东黄乾益拟减持不超3%股份",
    "href": "http://stock.jrj.com.cn/2022/12/05163537188888.shtml",
    "datetime": "2022-12-05 16:35:41",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：长兴茂达减持数过半 已减持2%股份",
    "href": "http://stock.jrj.com.cn/2022/11/30154437178074.shtml",
    "datetime": "2022-11-30 15:44:15",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：股东王晓鹏减持量过半 累计减持1.488%股份",
    "href": "http://stock.jrj.com.cn/2022/11/30154237178077.shtml",
    "datetime": "2022-11-30 15:42:01",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：减持数过半 湖州意诺特累积减持2.183%股份",
    "href": "http://stock.jrj.com.cn/2022/11/25175537167479.shtml",
    "datetime": "2022-11-25 17:55:19",
    "code": "688553"
  },
  {
    "title": "汇宇制药：股东长兴茂达、湖州意诺特拟合计减持不超6%公司股份",
    "href": "http://stock.jrj.com.cn/2022/11/17220737148262.shtml",
    "datetime": "2022-11-17 22:07:18",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：长兴茂达、湖州意诺特拟合计减持不超6%股份",
    "href": "http://stock.jrj.com.cn/2022/11/17154337146663.shtml",
    "datetime": "2022-11-17 15:43:18",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：第三季度净利降49.28%至6566.01万元",
    "href": "http://stock.jrj.com.cn/2022/10/30193637097745.shtml",
    "datetime": "2022-10-30 19:36:48",
    "code": "688553"
  },
  {
    "title": "本周A股解禁规模超500亿元 海尔生物、成大生物、汇宇制药解禁市值居前",
    "href": "http://stock.jrj.com.cn/2022/10/24075537076551.shtml",
    "datetime": "2022-10-24 07:55:15",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：股东黄乾益质押400万股",
    "href": "http://stock.jrj.com.cn/2022/09/19182637005560.shtml",
    "datetime": "2022-09-19 18:26:35",
    "code": "688553"
  },
  {
    "title": "汇宇制药：注射用阿扎胞苷获意大利上市许可",
    "href": "http://stock.jrj.com.cn/2022/09/01160736963032.shtml",
    "datetime": "2022-09-01 16:07:50",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：注射用阿扎胞苷获得意大利上市许可",
    "href": "http://stock.jrj.com.cn/2022/09/01160536963040.shtml",
    "datetime": "2022-09-01 16:05:54",
    "code": "688553"
  },
  {
    "title": "汇宇制药披露2022年半年报 实现营收8.33亿元",
    "href": "http://stock.jrj.com.cn/2022/08/26092436939153.shtml",
    "datetime": "2022-08-26 09:24:32",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)半年度净利润1.70亿元、同比下降34.13%",
    "href": "http://stock.jrj.com.cn/2022/08/25202336937169.shtml",
    "datetime": "2022-08-25 20:23:04",
    "code": "688553"
  },
  {
    "title": "汇宇制药：多西他赛注射液获得德国上市许可",
    "href": "http://stock.jrj.com.cn/2022/08/22163836921667.shtml",
    "datetime": "2022-08-22 16:38:14",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：多西他赛注射液获得德国上市许可",
    "href": "http://stock.jrj.com.cn/2022/08/22162636921631.shtml",
    "datetime": "2022-08-22 16:26:05",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)2021年度权益分派10派2.11元、股权登记日为8月19日",
    "href": "http://stock.jrj.com.cn/2022/08/15142336899922.shtml",
    "datetime": "2022-08-15 14:23:34",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：股东黄乾益质押1065万股",
    "href": "http://stock.jrj.com.cn/2022/08/11175036891439.shtml",
    "datetime": "2022-08-11 17:50:12",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：丙戊酸钠注射用浓溶液(5ml:0.5g)获批上市",
    "href": "http://stock.jrj.com.cn/2022/07/11171136799335.shtml",
    "datetime": "2022-07-11 17:11:14",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：奥沙利铂注射用浓溶液获德国上市许可",
    "href": "http://stock.jrj.com.cn/2022/05/25183236678412.shtml",
    "datetime": "2022-05-25 18:32:38",
    "code": "688553"
  },
  {
    "title": "汇宇制药股东黄乾益质押209万股 用于补充质押",
    "href": "http://stock.jrj.com.cn/2022/05/16201136652640.shtml",
    "datetime": "2022-05-16 20:11:04",
    "code": "688553"
  },
  {
    "title": "汇宇制药2022年第一季度净利1.19亿同比下滑11.49% 研发投入增加",
    "href": "http://stock.jrj.com.cn/2022/05/03191136546540.shtml",
    "datetime": "2022-05-03 19:11:52",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：260.4295万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2022/04/18183836386222.shtml",
    "datetime": "2022-04-18 18:38:37",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：英国全资子公司产品醋酸奥曲肽注射液获批上市",
    "href": "http://stock.jrj.com.cn/2022/04/11174436305384.shtml",
    "datetime": "2022-04-11 17:44:13",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：英国全资子公司左乙拉西坦注射用浓溶液获批上市",
    "href": "http://stock.jrj.com.cn/2022/04/08173536273094.shtml",
    "datetime": "2022-04-08 17:35:19",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：丙戊酸钠注射用浓溶液获英国的药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/04/07200936269172.shtml",
    "datetime": "2022-04-07 20:09:36",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：拟将1.35亿元超募资金用于永久补流",
    "href": "http://stock.jrj.com.cn/2022/04/07084536266614.shtml",
    "datetime": "2022-04-07 08:45:55",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：拟使用不超40亿元暂时闲置自有资金购买理财产品",
    "href": "http://stock.jrj.com.cn/2022/04/07084336266615.shtml",
    "datetime": "2022-04-07 08:43:13",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：2022年度拟向金融机构申请不超5亿元综合授信",
    "href": "http://stock.jrj.com.cn/2022/04/07083136266576.shtml",
    "datetime": "2022-04-07 08:31:37",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：左乙拉西坦注射用浓溶液获批上市",
    "href": "http://stock.jrj.com.cn/2022/04/07083036266577.shtml",
    "datetime": "2022-04-07 08:30:04",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)2021年度净利升29.87%至4.46亿元 拟10派2.11元",
    "href": "http://stock.jrj.com.cn/2022/04/07082836266547.shtml",
    "datetime": "2022-04-07 08:28:00",
    "code": "688553"
  },
  {
    "title": "汇宇制药股东黄乾益质押795万股 用于融资担保",
    "href": "http://stock.jrj.com.cn/2022/04/01201036248595.shtml",
    "datetime": "2022-04-01 20:10:47",
    "code": "688553"
  },
  {
    "title": "汇宇制药股东黄乾益质押340万股 用于融资担保",
    "href": "http://stock.jrj.com.cn/2022/03/03201034517204.shtml",
    "datetime": "2022-03-03 20:10:23",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：持股5%以上股东黄乾益质押340万股",
    "href": "http://stock.jrj.com.cn/2022/03/03174534516590.shtml",
    "datetime": "2022-03-03 17:45:54",
    "code": "688553"
  },
  {
    "title": "汇宇制药2021年赚4.53亿元，同比增长31.96%",
    "href": "http://stock.jrj.com.cn/2022/02/15110934352834.shtml",
    "datetime": "2022-02-15 11:09:15",
    "code": "688553"
  },
  {
    "title": "汇宇制药2021年净利4.53亿同比增长31.96% 注射用培美曲塞二钠销售增长",
    "href": "http://stock.jrj.com.cn/2022/02/14195234346068.shtml",
    "datetime": "2022-02-14 19:52:59",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)业绩快报：2021年度净利润升31.96%至4.53亿元",
    "href": "http://stock.jrj.com.cn/2022/02/14180434345489.shtml",
    "datetime": "2022-02-14 18:04:32",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：注射用硼替佐米获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/02/09170634313721.shtml",
    "datetime": "2022-02-09 17:06:36",
    "code": "688553"
  },
  {
    "title": "汇宇制药股东黄乾益质押508万股 用于融资担保",
    "href": "http://stock.jrj.com.cn/2022/01/28211034248726.shtml",
    "datetime": "2022-01-28 21:10:57",
    "code": "688553"
  },
  {
    "title": "汇宇制药股东王晓鹏质押350万股 用于融资担保",
    "href": "http://stock.jrj.com.cn/2022/01/18205134171250.shtml",
    "datetime": "2022-01-18 20:51:08",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：股东王晓鹏质押350万股",
    "href": "http://stock.jrj.com.cn/2022/01/18172434170178.shtml",
    "datetime": "2022-01-18 17:24:58",
    "code": "688553"
  },
  {
    "title": "汇宇制药：拟使用超募资金用于高端绿色药物产业延链项目",
    "href": "http://stock.jrj.com.cn/2022/01/11215134147817.shtml",
    "datetime": "2022-01-11 21:51:39",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：拟以5000万元认购文周君喆的基金份额",
    "href": "http://stock.jrj.com.cn/2022/01/11205134147615.shtml",
    "datetime": "2022-01-11 20:51:44",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：拟使用部分超募资金28861万元用于高端绿色药物产业延链项目",
    "href": "http://stock.jrj.com.cn/2022/01/11204834147599.shtml",
    "datetime": "2022-01-11 20:48:40",
    "code": "688553"
  },
  {
    "title": "汇宇制药股东黄乾益质押885万股 用于融资担保",
    "href": "http://stock.jrj.com.cn/2021/12/30213234088460.shtml",
    "datetime": "2021-12-30 21:32:57",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：股东黄乾益质押885万股",
    "href": "http://stock.jrj.com.cn/2021/12/30203234088205.shtml",
    "datetime": "2021-12-30 20:32:04",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：投资500万美元在美国设立全资子公司",
    "href": "http://stock.jrj.com.cn/2021/12/14162934014602.shtml",
    "datetime": "2021-12-14 16:29:00",
    "code": "688553"
  },
  {
    "title": "汇宇制药股东黄乾益质押550万股 用于融资担保",
    "href": "http://stock.jrj.com.cn/2021/12/10183133995470.shtml",
    "datetime": "2021-12-10 18:31:58",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：股东黄乾益质押550万股",
    "href": "http://stock.jrj.com.cn/2021/12/10161233994714.shtml",
    "datetime": "2021-12-10 16:12:51",
    "code": "688553"
  },
  {
    "title": "汇宇制药：注射用盐酸苯达莫司汀纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03155633960171.shtml",
    "datetime": "2021-12-03 15:56:49",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：控股股东、实控人丁兆所持相关股份延长锁定期",
    "href": "http://stock.jrj.com.cn/2021/11/24161433914398.shtml",
    "datetime": "2021-11-24 16:14:37",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：盐酸帕洛诺司琼注射液已获批注册",
    "href": "http://stock.jrj.com.cn/2021/11/07160433820152.shtml",
    "datetime": "2021-11-07 16:04:32",
    "code": "688553"
  },
  {
    "title": "汇宇制药：盐酸帕洛诺司琼注射液获药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/11/07155033820144.shtml",
    "datetime": "2021-11-07 15:50:50",
    "code": "688553"
  },
  {
    "title": "汇宇制药使用16亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/invest/2021/11/01091633795963.shtml",
    "datetime": "2021-11-01 09:16:00",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)披露上市发行结果：遭弃购21914股 由联席主承销商包销",
    "href": "http://stock.jrj.com.cn/2021/10/18145933710521.shtml",
    "datetime": "2021-10-18 14:59:24",
    "code": "688553"
  },
  {
    "title": "汇宇制药网上发行中签结果出炉 末“4”位数为3686、8686",
    "href": "http://stock.jrj.com.cn/2021/10/14111033689810.shtml",
    "datetime": "2021-10-14 11:10:11",
    "code": "688553"
  },
  {
    "title": "【兑奖啦】科创板凯尔达、中自科技、汇宇制药网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2021/10/13194533686326.shtml",
    "datetime": "2021-10-13 19:45:26",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：中信建投投资获配190.8万股 网上摇号中签号共30812个",
    "href": "http://stock.jrj.com.cn/2021/10/13193733686298.shtml",
    "datetime": "2021-10-13 19:37:10",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)：网上发行最终中签率为0.02872418%",
    "href": "http://stock.jrj.com.cn/2021/10/12191033680593.shtml",
    "datetime": "2021-10-12 19:10:51",
    "code": "688553"
  },
  {
    "title": "汇宇制药(688553.SH)IPO定价为38.87元/股 10月12日申购",
    "href": "http://stock.jrj.com.cn/2021/10/10160333663687.shtml",
    "datetime": "2021-10-10 16:03:31",
    "code": "688553"
  },
  {
    "title": "证监会同意谊众药业、汇宇制药、纽威数控、振华新材科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/08/04085933199577.shtml",
    "datetime": "2021-08-04 08:59:36",
    "code": "688553"
  },
  {
    "title": "证监会同意汇宇制药、上海谊众、纽威数控、振华新材科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/08/03214933197806.shtml",
    "datetime": "2021-08-03 21:49:00",
    "code": "688553"
  },
  {
    "title": "即将成功“上岸”！宏微科技、汇宇制药科创板IPO提交注册",
    "href": "http://stock.jrj.com.cn/2021/06/03101832868016.shtml",
    "datetime": "2021-06-03 10:18:49",
    "code": "688553"
  },
  {
    "title": "汇宇制药过会：今年IPO过关第161家 中信建投过11单",
    "href": "http://stock.jrj.com.cn/2021/05/27101132827922.shtml",
    "datetime": "2021-05-27 10:11:00",
    "code": "688553"
  },
  {
    "title": "汇宇制药科创板首发今日上会：轻研发重销售，单一产品集中度超90%",
    "href": "http://stock.jrj.com.cn/ipo/2021/05/26100532821526.shtml",
    "datetime": "2021-05-26 10:05:30",
    "code": "688553"
  },
  {
    "title": "两家上会！汇宇制药、卓锦环保5月26日将接受科创板IPO审核",
    "href": "http://stock.jrj.com.cn/2021/05/20101832785774.shtml",
    "datetime": "2021-05-20 10:18:21",
    "code": "688553"
  },
  {
    "title": "汇宇制药答科创板二轮11问 科创板定位、违法行为再被关注",
    "href": "http://stock.jrj.com.cn/2021/04/01092232261107.shtml",
    "datetime": "2021-04-01 09:22:14",
    "code": "688553"
  },
  {
    "title": "汇宇制药回复科创板IPO首轮问询：毛利率、特别表决权被关注",
    "href": "http://stock.jrj.com.cn/2021/02/23162332012744.shtml",
    "datetime": "2021-02-23 16:23:41",
    "code": "688553"
  },
  {
    "title": "重销售、轻研发 汇宇制药“同股不同权”IPO面临考验",
    "href": "http://stock.jrj.com.cn/ipo/2021/01/05071431631502.shtml",
    "datetime": "2021-01-05 07:14:07",
    "code": "688553"
  },
  {
    "title": "汇宇制药：专注抗肿瘤和注射剂药物领域",
    "href": "http://stock.jrj.com.cn/2020/12/10131231455487.shtml",
    "datetime": "2020-12-10 13:12:38",
    "code": "688553"
  }
]